Migraine
📧 Sign up to get email alerts when something new happens for Migraine.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2025-04-16Clinical Trial Update: Analysis of Vestibular Compensation Following Clinical Intervention for Vestibular Schwannoma [NA]
A clinical trial (NCT04196933) evaluating vestibular compensation after intervention for vestibular schwannoma has been withdrawn.
-
FDA approval · 2025-04-15FDA Approved: ALMOTRIPTAN MALATE — Supplemental Application (Mylan Pharmaceuticals Inc.)
The FDA approved a supplemental application to allow the sale of almotriptan malate (almotriptan) as a generic product by Mylan for acute tr…
-
FDA approval · 2025-04-15FDA Approved: DIVALPROEX SODIUM — Supplemental Application (Camber Pharmaceuticals, Inc.)
FDA approved Camber Pharmaceuticals' supplemental application for divalproex sodium.
-
CLINICAL_TRIALS trial_result · 2025-04-11Clinical Trial Update: Oxygen in Migraine Treatment
A completed clinical trial from Ankara Ataturk Sanatorium Training and Research Hospital evaluated oxygen therapy for migraine treatment (NC…
-
CLINICAL_TRIALS research · 2025-04-10Clinical Trial Update: Assessment of the Effectiveness of Virtual Reality as a Learning Tool for Relaxation Techniques in Reducing Pediatric Migraines and Tension Type Headache [NA]
A clinical investigation is evaluating whether virtual reality-based relaxation training can reduce migraines and tension-type headaches in …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-04-08Clinical Trial Update: Cross-cultural Adaptation, Reliability and Validity of the Turkish Version of the Headache Disability Questionnaire
This clinical trial update reports the cross-cultural adaptation of the Headache Disability Questionnaire into Turkish and assesses its reli…
-
CLINICAL_TRIALS research · 2025-04-08Clinical Trial Update: Cross-cultural Adaptation, Reliability and Validity of the Turkish Version of the Headache Impact Questionnaire
Validation study assessing the cross-cultural adaptation, reliability, and validity of the Turkish version of the Headache Impact Questionna…
-
CLINICAL_TRIALS research · 2025-04-08Clinical Trial Update: Migraines Accepted Laser Acupuncture Compared in Blood Test of MMP2 and CGRP [NA]
Clinical trial investigating laser acupuncture for migraine/headache with blood biomarker analysis (MMP2 and CGRP); currently recruiting.
-
CLINICAL_TRIALS research · 2025-04-07Clinical Trial Update: Emgality for Migraine in Breastmilk
This clinical trial update indicates that a study evaluating galcanezumab (Emgality) for migraine in breastfeeding is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2025-04-06Clinical Trial Update: Clinical Decision Support for Patient Migraine Management [NA]
A completed clinical trial evaluated a decision-support tool to aid migraine management. Results were posted on 2025-04-06.
-
EMA approval · 2025-04-04EMA Authorised: Ajovy (fremanezumab) — Teva GmbH
The European Medicines Agency authorised Ajovy (fremanezumab) by Teva GmbH for migraine disorders, marking EU marketing authorization for th…
-
CLINICAL_TRIALS research · 2025-04-03Clinical Trial Update: Tai Chi for the Prophylaxis of Episodic Migraine: the Efficacy Examination and Mechanism Exploration [NA]
Researchers at The Hong Kong Polytechnic University are conducting a trial to evaluate whether Tai Chi can prevent episodic migraines and to…
-
CLINICAL_TRIALS trial_result · 2025-03-30Clinical Trial Update: The Effect of Galcanezumab-gnlm on Post-Traumatic, Migrainous Headaches [Phase 4]
A Phase 4 clinical trial evaluating galcanezumab-gnlm for post-traumatic migrainous headaches has completed.
-
CLINICAL_TRIALS trial_result · 2025-03-30Clinical Trial Update: A Real-world, Prospective Observational Study of Rimegepant ODT for the Acute Treatment of Migraine Attacks in Adults.
Pfizer-sponsored real-world observational study evaluating the acute treatment of migraine attacks in adults with rimegepant ODT. The study …
-
FDA approval · 2025-03-28FDA Approved: SUMATRIPTAN — Supplemental Application (Rising Pharma Holdings, Inc.)
The FDA approved a supplemental application for Sumatriptan submitted by Rising Pharma Holdings, Inc.
-
FDA approval · 2025-03-27FDA Approved: DIVALPROEX SODIUM — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for divalproex sodium (divalproex) by Aurobindo Pharma Limited. The approval pertains to the generic…
-
CLINICAL_TRIALS trial_result · 2025-03-27Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention [Phase 2, Phase 3]
Pfizer's oral zavegepant was evaluated for migraine prevention in Phase 2/Phase 3 trials. The study was terminated and results have been pos…
-
CLINICAL_TRIALS research · 2025-03-27Clinical Trial Update: Study on 30 Outpatients with Chronic Migraine Treated with Well-Being Therapy or with a Control Therapy [NA]
A clinical trial is recruiting 30 outpatients with chronic migraine to compare Well-Being Therapy with a control therapy.
-
FDA approval · 2025-03-26FDA Approved: RIZATRIPTAN BENZOATE — Supplemental Application (Panacea Biotec Limited)
FDA approved a supplemental application for Rizatriptan Benzoate by Panacea Biotec Limited. The approval makes a generic rizatriptan benzoat…
-
CLINICAL_TRIALS research · 2025-03-25Clinical Trial Update: A Pragmatic Trial of Machine Prescription for Migraine
A pragmatic clinical trial evaluating machine-assisted prescription for migraine is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2025-03-24Clinical Trial Update: (Botox) Mechanisms of Action in Altering the Molecular Environment in Which Pain Fibers Exist [Phase 4]
Phase 4 trial evaluating onabotulinumtoxinA (Botox) for migraine to understand its mechanism of action on the molecular environment around p…
-
FDA approval · 2025-03-21FDA Approved: NURTEC ODT — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
FDA supplemental application for Nurtec ODT (rimegepant sulfate) submitted by Pfizer Laboratories Div Pfizer Inc to modify labeling and/or e…
-
FDA approval · 2025-03-21FDA Approved: AJOVY — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
The FDA approved a supplemental application for AJOVY (fremanezumab-vfrm) from Teva Pharmaceuticals USA, Inc., resulting in an approved upda…
-
FDA approval · 2025-03-21FDA Approved: VYEPTI — Supplemental Application (Lundbeck Pharmaceuticals LLC)
The FDA approved a supplemental application for VYEPTI (eptinezumab-jjmr) from Lundbeck Pharmaceuticals LLC.
-
FDA approval · 2025-03-21FDA Approved: ZAVZPRET — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
FDA approved a supplemental application for ZAVZPRET (zavegepant) submitted by Pfizer Laboratories Div Pfizer Inc.